Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > This gives me less and less and less confidence

<< Previous

Bullboard Posts

Next >>

Comment by AngelaLon Feb 06, 2021 8:17pm

147 Views

Post# 32494463

RE:This gives me less and less and less confidence

I am relatively new to Kalytera so don't know all the history but I certainly know of Salzman. He is a famous scientist and physician - invented a number of major medical breakthroughs at Inotek, Radikal, Orphan, etc. Don't know how Kalytera was able to succeed in getting him on board with a strategic collaboration. I am pretty sure he brought R-107 to Kalytera for Covid. Salzman is the real deal - this isn't a "shell game".

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario